Target Therapeutics' Guglielmi Detachable Coil gains FDA clearance.

TARGET THERAPEUTICS TO BEGIN U.S. SALES OF GDC COIL IMMEDIATELY at the approximately 20 sites where neuroradiologists and neurosurgeons were trained in use of the device for clinical trials. Target announced Sept. 14 that it received FDA clearance of the Guglielmi Detachable Coil (GDC) for treatment of intracranial aneurysms that are "considered inoperable or very high risk for surgery."